Felege Hiwot Comprehensive Specialized Hospital, Ethiopia
Research
Immuno-Hematological Profiles of Ethiopian Cutaneous Leishmaniasis Patients before and During Treatment with Sodium Stibogluconate
Author(s): Bizuayehu Gashaw*, Endalew Yizengaw, Zelalem Mehari, Banchwossen Sebsibe, Feiza Seid, Tsedalu Alemu and Endalkachew Nibret
Background: Leishmania parasite is known to secrete surface proteins that help evade the host's immune response. After anti-leishmaniasis therapy, the disease can persist, particularly under immunosuppression, leading to a high risk of relapse. Neutrophils are the first responders followed by macrophages and dendritic cells, but sand fly saliva inhibits their effectiveness. In Ethiopia, Sodium Stibo Gluconate (SSG) is commonly used to treat Cutaneous Leishmaniasis (CL). But, much is not known about patients' immuno-hematological profiles before the initiation of treatment and during treatment. We hypothesized that treatment would enhance the immuno-hematological profile of Ethiopian CL patients.
Materials and Method: A longitudinal study was conducted from September 2022 to August 2024 at Adiss Alem Primary Hospital in Bahir Dar city.. View More»
